Investigation of Chemical Stability and Sterility of Morphine in Intrathecal Pumps for Long-Term Pain Management

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorMeir Medical Center

About this trial

Intrathecal drug delivery systems (IDDS) are effective for managing chronic pain by delivering medications directly into the cerebrospinal fluid. Morphine, a primary opioid used in these systems, must remain chemically stable and sterile over prolonged periods to ensure patient safety and therapeutic efficacy . Previous studies have evaluated morphine stability in vitro under simulated conditions , indicating minimal degradation in saline over time . However, there is limited real-world data regarding the residual morphine in pump reservoirs after extended use . This study seeks to bridge this gap by analyzing morphine aspirated from intrathecal pumps during routine refills in a clinical setting, while comparing it to in vitro samples taken in the clinic .. Objectives Primary Objective: To determine the chemical stability of morphine in intrathecal pump reservoirs over a 3 to 6-month period of clinical use.

Secondary Objective: To assess the sterility of residual morphine and evaluate any microbial contamination.

Eligibility criteria

Qualifiers

Receiving intrathecal Morphine (Rafa Laboratories, 20 mg/ml; registration no. 106-25-28981-00).

Scheduled for a routine pump refill procedure at an interval of 3 to 6 months.

Disqualifiers

Evidence of active systemic infection or localized infection at the pump implantation site.

History of recent pump malfunction or refills occurring outside the standard 3 to 6-month window.

Inability to provide informed consent.

Pregnant patients.

Trial design

Treatments tested in this trial

  • Culturing and testing chemical stability

Treatment groups

5 Participants
are divided into 1 treatment group

Sponsors and collaborators